Stay updated with breaking news from Pfizer Board. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Company data found the Pfizer vaccine was 90.7% effective against symptomatic disease in children ages 5 to 11 and the FDA said the benefits in giving the vaccine to children outweighed the risks.
As the number of new daily cases of Covid-19 continues to fall in the US, the country awaits a major milestone that could provide another critical tool in the fight against the pandemic -- the first vaccine for 5 to 11-year-olds.
Company data found the Pfizer vaccine was 90.7% effective against symptomatic disease in children ages 5 to 11 and the FDA said the benefits in giving the vaccine to children outweighed the risks.
Company data found the Pfizer vaccine was 90.7% effective against symptomatic disease in children ages 5 to 11 and the FDA said the benefits in giving the vaccine to children outweighed the risks.
Company data found the Pfizer vaccine was 90.7% effective against symptomatic disease in children ages 5 to 11 and the FDA said the benefits in giving the vaccine to children outweighed the risks.